#USA #Salt Lake City #Lipocine #LPCN #Michael Grissinger

Lipocine Welcomes Michael J. Grissinger to Board of Directors

Lipocine Inc., a publicly traded biopharmaceutical company known for its innovative approach to oral therapeutics, has announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026. This strategic move is expected to bolster the company’s direction as it advances its product pipeline and seeks new partnerships.

Experience Matters

Michael J. Grissinger brings over 20 years of substantial experience at Johnson & Johnson, where he held senior management positions, including Vice President of Worldwide Pharmaceutical Licensing and corporate development. His expertise in managing licensing agreements and mergers and acquisitions makes him a valuable addition to Lipocine’s leadership team. Dana Ono, Ph.D., Chairman of the Board of Lipocine, stated, "Mike's extensive deal-making experience will be invaluable as we work to advance our pipeline and pursue partnerships for our assets."

Before his impressive tenure at Johnson & Johnson, Grissinger spent 12 years at Ciba-Geigy in various roles focused on finance, marketing, and business development. These experiences position him well to contribute to Lipocine's strategic initiatives.

Currently, Grissinger serves on the boards of both Aprea Therapeutics and Adicet Bio, demonstrating his ongoing commitment to the biotech sector. He also advises several privately-held biotech firms, bringing a wealth of knowledge to the table.

A Promising Future

In his statement about joining Lipocine, Grissinger expressed enthusiasm for the company's innovative approach. He acknowledged Lipocine's commitment to leveraging its proprietary oral delivery technology, emphasizing the potential of its diverse portfolio of commercial and clinical assets. "I look forward to collaborating with the Board and management to advance these programs, delivering meaningful value for patients and investors alike," he stated.

Lipocine's development pipeline is rich with drug candidates aimed at addressing significant medical needs. Among them are LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, and others targeting conditions such as essential tremor and liver cirrhosis. Notably, TLANDO, Lipocine's novel testosterone oral prodrug, has already received FDA approval for managing testosterone deficiency in adult males.

The addition of Grissinger to the Board lends credibility to Lipocine's strategic ambitions and is expected to enhance its capacity to navigate the complexities of the biopharmaceutical industry. His insights and experience could position the company favorably for future growth and partnership opportunities, particularly as it looks to expand its offerings in the competitive therapeutic landscape.

Summary

In summary, the appointment of Michael J. Grissinger to Lipocine's Board of Directors marks a significant step forward for the company as it seeks to leverage new opportunities in the pharmaceutical sector. With his extensive background in licensing and corporate development, Grissinger is poised to make a positive impact on Lipocine's strategic direction and enhance its potential for success in the rapidly evolving biotech marketplace.